Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche enters into a definitive agreement to acquire Poseida

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 26, 2024 8:24pm

52 Views

Post# 36332534

RE:RE:RE:RE:RE:RE:RE:Roche enters into a definitive agreement to acquire Poseida

Both Roche and Novartis seem "woke" to ONCY's potential with pelareorep's ability to synergize with other biologics like immune checkpoint inhibitors, bispecifics, ADCs, CAR-T therapies, as well as small molecules like CD4, CD6, and PARP inhibitors, as just several examples.

Now that ONCY has the ACCELERATED APPROVAL and Breakthrough Therapy Designation open, the early approval of pelareorep has exponentially increased.

<< Previous

Bullboard Posts

Next >>

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal